(Il Sole 24 Ore Radiocor) – Milan, Oct 03 – The French pharmaceutical group Sanofi and its American counterpart Bristol-Myers Squibb have announced a restructuring of their alliance, with the acquisition by the French group of the exclusive rights on the drugs Plavix (anticoagulant) and Avapro/Avalide (treatment for hypertension) in the major markets. The two drugs, until now, were jointly distributed and accounted for a large portion of the group's revenues. Under the revised agreement, effective January 1, 2013, Bristol-Myers Squibb will return the rights to Plavix and Avapro/Avalide to Sanofi in all markets except Plavix in the U.S. and Puerto Rico, giving Sanofi sole control and the freedom to operate commercially. In return, Bristol-Myers Squibb will receive royalty payments on worldwide sales of Plavix, excluding the US and Puerto Rico, and worldwide sales of Avapro/Avalide, both through 2018.
(RADIOCOR) 03-10-12 08:17:26 (0045) 5 NNNN
